尼泊卡利单抗

Search documents
强生(JNJ.US)终止类风湿性关节炎联合疗法研发 与艾伯维(ABBV.US)修美乐联用未达预期
Zhi Tong Cai Jing· 2025-08-29 13:28
Core Viewpoint - Johnson & Johnson (JNJ.US) has decided to terminate the joint development project of its experimental antibody drug, nipocalimab, with anti-tumor necrosis factor alpha (anti-TNFα) therapy for the treatment of rheumatoid arthritis (RA) due to the results of its Phase 2a DAISY proof-of-concept study, which showed no significant clinical benefits over the use of anti-TNFα therapy alone [1] Group 1 - The combination therapy of nipocalimab and anti-TNFα did not demonstrate significant clinical benefits in RA patients compared to anti-TNFα therapy alone, despite no new safety issues being reported [1] - Johnson & Johnson has decided not to advance the clinical development of this combination therapy in the RA treatment area based on the study findings [1] - Nipocalimab was previously considered a key research project in Johnson & Johnson's rheumatology portfolio, with projected peak annual sales exceeding $5 billion [1] Group 2 - The setback highlights the high-risk nature of innovative drug development, particularly in the competitive field of autoimmune disease treatments [1] - Humira, AbbVie's blockbuster drug, generated nearly $21 billion in sales in 2021 but is facing sales pressure starting in 2023 due to the introduction of biosimilars by U.S. companies [1]